NCT02209753View on ClinicalTrials.gov

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

September 30, 2002

Conditions
Psoriasis
Interventions
DRUG

BIRB 796 BS, low dose

DRUG

BIRB 796 BS, medium dose 1

DRUG

BIRB 796 BS, medium dose 2

DRUG

BIRB 796 BS, high dose

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02209753 - BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis | Biotech Hunter | Biotech Hunter